The Role of Genetic Factors in the Development of Myocardial Infarction in the Kazakh Population

Heart Attack Clinical Trial

Official title:

Preventive and Personalized Medicine (2021-2023)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05090618
• Other study ID #: 1187
• Status: Completed
• Start date: October 23, 2021
• Est. completion date: January 20, 2023

Study information

• Verified date: March 2023
• Source: Asfendiyarov Kazakh National Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a GWAS study that aims to identify possible candidate genes associate to heart attack by exploring single nucleotide polymorphism (SNP) in a group of heart attack, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with heart attack

Description:

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: January 20, 2023
• Est. primary completion date: January 20, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Persons of Kazakh nationality
• Age up to 59 years inclusive at the time of primary myocardial infarction
• Myocardial infarction was established in accordance with the EOC criteria: An increase and / or decrease in the level of cardiac troponin must be combined with at least one of the following: • Symptoms of myocardial ischemia • Newly occurring ischemic changes on the ECG • The appearance of a pathological Q wave • Identification according to imaging data methods of new areas of non-viable myocardium, or new areas of local contractility disorders of presumably ischemic etiology • Detection of a thrombus in the coronary arteries according to coronary angiography
• Presence of coronary angiography
• Persons able and willing to provide written informed consent;

Exclusion Criteria:

• Age at primary myocardial infarction 60 years and older
• Heart defects, congenital and acquired
• Non-ischemic cardiomyopathies
• Autoimmune diseases
• Diabetes mellitus at the time of development of primary myocardial infarction
• Terminal stages of renal and hepatic failure

Related Conditions & MeSH terms

• Heart Attack
• Myocardial Infarction

Intervention

Genetic:
• DNA analysis
GWAS

Locations

Country	Name	City	State
Kazakhstan	Kazakhstan	Almaty

Sponsors (1)

Lead Sponsor	Collaborator
Asfendiyarov Kazakh National Medical University

Country where clinical trial is conducted

Kazakhstan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of SNPs associated with Heart Attack	Using GWAS to identify candidate genes associate with Heart Attack	1 year